DOCSLIB.ORG

Piroxicam 10Mg and 20Mg Capsules Celecoxib Or Acetylsalicylic Acid (Aspirin), a Not Known (Frequency Cannot Be Estimated No Longer Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Piroxicam 10Mg and 20Mg Capsules Celecoxib Or Acetylsalicylic Acid (Aspirin), a Not Known (Frequency Cannot Be Estimated No Longer Use • drowsiness Reporting of side effects • ringing in ears (tinnitus) If you get any side effects, talk to your doctor, • abdominal pain/discomfort pharmacist or nurse. This includes any possible • constipation side effects not listed in this leaflet. • diarrhoea Package leaflet: Information for the patient • wind You can also report side effects directly via the • feeling sick (nausea) Yellow Card Scheme at: Piroxicam 10mg and 20mg • being sick (vomiting) www.mhra.gov.uk/yellowcard or search for • indigestion MHRA Yellow Card in the Google Play or Apple Capsules • itching App Store. Read all of this leaflet carefully before 2 What you need to know before • skin rash By reporting side effects you can help provide • swelling of the feet, hands or other parts of you start taking this medicine because it you take Piroxicam capsules more information on the safety of this contains important information for you. the body (oedema) medicine. • weight increase. • Keep this leaflet. You may need to read Do not take Piroxicam capsules if you: it again. • are allergic to piroxicam or any of the other 5 How to store Piroxicam capsules Uncommon (may affect up to • If you have any further questions, ask ingredients of this medicine (listed in section 1 in 100 people): Keep this medicine out of the sight and reach 6); an allergic reaction to other NSAIDs or • blurred vision your doctor or pharmacist. of children. • This medicine has been prescribed for any other medications, especially serious • fast or pounding heartbeat Store below 25°C in a dry place. Protect from skin reactions (regardless of severity) such as • sore mouth and/or lips you only. Do not pass it on to others. It exfoliative dermatitis (intense reddening of light. may harm them, even if their signs of • decreased/low blood sugar level. Do not take this medicine after the expiry date skin, with skin peeling off in scales or layers), which is stated on the label/carton/bottle after illness are the same as yours. Stevens-Johnson syndrome (symptoms are a Rare (may affect up to • If you get any side effects, talk to your rash, blistering or peeling of the skin, mouth, 1 in 1,000 people): ‘EXP’ . The expiry date refers to the last day of that month. doctor or pharmacist. This includes any eyes or genitals) or toxic epidermal necrolysis • kidney inflammation (a disease with blistering and peeling of the • kidney damage possible side effects not listed in this Do not throw away any medicines via leaflet. See section 4. top layer of skin). • change in urine output or appearance • are taking other NSAIDs such as ibuprofen, • kidney pain or pain in abdomen. wastewater or household waste. Ask your • The full name of this medicine is pharmacist how to throw away medicines you Piroxicam 10mg and 20mg Capsules celecoxib or acetylsalicylic acid (aspirin), a Not known (frequency cannot be estimated no longer use. These measures will help protect substance present in many medicines used but within this leaflet it will be referred to relieve pain and lower fever. from the available data): the environment. to as Piroxicam capsules. • abnormalities in the blood e.g. decreased • have previously had or currently have a stomach or intestinal ulcer, bleeding or haemoglobin 6 Contents of the pack and other • fluid retention information What is in this leaflet: perforation. • depression 1 What Piroxicam capsules are and • have, or have previously had disorders of • dream abnormalities What Piroxicam capsules contain what they are used for the stomach or intestines such as ulcerative • changes in sleep patterns • The active substance (the ingredient that colitis, Crohn’s disease, gastrointestinal 2 What you need to know before • mental confusion makes the medicine work) is piroxicam. Each cancers or diverticulitis (inflamed or infected • mood alterations capsule contains either 10mg or 20mg of the you take Piroxicam capsules pouches/pockets in the colon). • nervousness active ingredient. 3 How to take Piroxicam capsules • are taking anticoagulants, such as warfarin, to prevent blood clots. • pins and needles • The other ingredients are carmellose sodium, 4 Possible side effects • suffer from severe heart failure. • eye irritations gelatin, lactose, magnesium stearate, maize 5 starch, polysorbate, shellac glaze, E127, E132 How to store Piroxicam capsules • are in the last three months of pregnancy. • swollen eyes 6 • hearing impairment (10mg only), E171, E172 and propylene Contents of the pack and other glycol. If any of the above apply to you, tell your • high blood pressure information doctor immediately and do not take • inflammation of the blood vessels Piroxicam capsules. • shortness of breath What Piroxicam capsules look like and • constriction of the muscles lining the airways contents of the pack Piroxicam 10mg capsules are pink and 1 What Piroxicam capsules are and Potentially life-threatening skin rashes (DRESS of lungs (bronchial) syndrome, Stevens-Johnson syndrome, toxic • nose bleeds turquoise hard gelatin capsules printed “C” and what they are used for the identifying letters “YA” in black and are in epidermal necrolysis) have been reported • inflammation of the stomach lining (gastritis) Piroxicam belongs to a group of medicines with the use of piroxicam, appearing initially • stomach (peptic) ulcers pack sizes of 56. Piroxicam 20mg capsules are pink hard gelatin called Non-Steroidal Anti-Inflammatory Drugs as reddish target-like spots or circular patches • upset stomach (NSAIDs). This means it will help to relieve pain often with central blisters on the trunk. • kidney inflammation possibly causing blood capsules printed “C” and the identifying letters “YB” in black and are in pack sizes of 28. and reduce swelling affecting joints. Piroxicam Additional signs to look for include: ulcers in the in the urine or pinkish urine, rashes, joint is used to relieve some symptoms caused by mouth, throat, nose, genitals and conjunctivitis pain, breathing problems or tiredness Marketing Authorisation Holder and osteoarthritis (joint disease), rheumatoid (red and swollen eyes). These potentially life- • hair loss Manufacturer arthritis and ankylosing spondylitis threatening skin rashes are often accompanied • rashes, peeling, redness, tenderness, Accord, Barnstaple, EX32 8NS, UK. (rheumatism of the spine), such as swelling, by flu-like symptoms. The rash may progress thickening or scaling of skin stiffness and joint pain. This medicine does not to widespread blistering or peeling of the skin. • fixed drug eruption (may look like round or This leaflet was last revised in July 2021. cure arthritis and will help you only as long as The highest risk for occurrence of serious skin oval patches of redness and swelling of the you continue to take it. reactions is within the first weeks of treatment. skin), blistering (hives), itching Your doctor will only prescribe Piroxicam to If you have developed Stevens-Johnson • loosening or splitting of fingernails you when you have had unsatisfactory relief of syndrome or toxic epidermal necrolysis with • increased sensitivity of the skin to sunlight symptoms with other NSAIDs. the use of Piroxicam, you must not be re- • decreased fertility started on Piroxicam at any time. • feeling unwell, general aches and pains If you develop a rash or skin symptoms, • weight decrease. you should stop taking Piroxicam capsules immediately, seek prompt medical advice and tell your doctor that you are taking this Continued top of next column medicine. 51000959 BBBB1679 Continued over page page 4 page 1 260x210 Leaflet Reel Fed Bi Fold Profile (BST) Piroxicam 10 & 20mg hard capsule PIL - UK Piroxicam Capsules approved for print/date Item number: BBBB1679 Colours Non Printing Colours 10, 20mg x 28, 56 (UK) 1. Black 1. Profile Originator: RH Dimensions: 260x210 JDE No.: 51000959 Origination Date: 22-06-21 Min Body Text Size: 8pts 2. 2. Revision Date: 02-07-21 Supplier: Accord Barnstaple 3. 3. Dimensions: 260x210 (Reel Fed) Revised By: RH 4. Component: Leaflet for Bottle 5. Proof Round Technical Date sent: n/a Pharmacode: 7347 6. 02 Approval Date received: n/a Date Sent: 27/05/21 [email protected] Technologist: T. Hull Cartons and label leaflets only Technically Approved (labels only when specified) German GTIN 14 (incorporating PZN): * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 7 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.02.2020 Take special care with Piroxicam Patients over 70 years of age If you are trying to become pregnant or If you have any further questions on the capsules If you are over 70 years old, your doctor may being investigated for infertility, withdrawal use of this medicine, ask your doctor or Before prescribing Piroxicam capsules, your wish to minimise the length of your treatment of Piroxicam capsules should be considered. pharmacist. doctor will assess the benefits this medicine and to see you more often while you are taking Piroxicam capsules may increase the risk of may give you against your risk of developing Piroxicam capsules. You should not take this miscarriage in early pregnancy. 4 Possible side effects side effects. Your doctor may need to give you medicine if you are over 80 years of age. check-ups and will tell you how often you need Driving and using machines Like all medicines, this medicine can cause side to be checked during treatment with Piroxicam Other medicines and Piroxicam capsules These capsules can cause some people to feel effects, although not everybody gets them. capsules. Tell your doctor or pharmacist if you are dizzy, drowsy, tired or have problems with taking, have recently taken or might take any their vision. If you are affected, do not drive or Stop taking Piroxicam capsules and contact Medicines such as Piroxicam capsules may be other medicines, even medicines you bought operate machinery.
Load more

Recommended publications
  • FDA-Approved Drugs with Potent in Vitro Antiviral Activity Against Severe Acute Respiratory Syndrome Coronavirus 2
    pharmaceuticals Article FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2 1, , 1, 2 1 Ahmed Mostafa * y , Ahmed Kandeil y , Yaseen A. M. M. Elshaier , Omnia Kutkat , Yassmin Moatasim 1, Adel A. Rashad 3 , Mahmoud Shehata 1 , Mokhtar R. Gomaa 1, Noura Mahrous 1, Sara H. Mahmoud 1, Mohamed GabAllah 1, Hisham Abbas 4 , Ahmed El Taweel 1, Ahmed E. Kayed 1, Mina Nabil Kamel 1, Mohamed El Sayes 1, Dina B. Mahmoud 5 , Rabeh El-Shesheny 1 , Ghazi Kayali 6,7,* and Mohamed A. Ali 1,* 1 Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt; [email protected] (A.K.); [email protected] (O.K.); [email protected] (Y.M.); [email protected] (M.S.); [email protected] (M.R.G.); [email protected] (N.M.); [email protected] (S.H.M.); [email protected] (M.G.); [email protected] (A.E.T.); [email protected] (A.E.K.); [email protected] (M.N.K.); [email protected] (M.E.S.); [email protected] (R.E.-S.) 2 Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt; [email protected] 3 Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, USA; [email protected] 4 Department of Microbiology and Immunology, Zagazig University, Zagazig 44519, Egypt; [email protected] 5 Pharmaceutics Department, National Organization for Drug Control and Research, Giza 12654, Egypt; [email protected] 6 Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas, Houston, TX 77030, USA 7 Human Link, Baabda 1109, Lebanon * Correspondence: [email protected] (A.M.); [email protected] (G.K.); [email protected] (M.A.A.) Contributed equally to this work.
    [Show full text]
  • Dentistry and Basic Non- Opioid Prescribing in Pain Dmitry M
    Dentistry and Basic Non- Opioid Prescribing in Pain Dmitry M. Arbuck, MD President, Indiana Polyclinic Clinical Associate Professor of Psychiatry and Pain Management, Marian University College of Osteopathic Medicine Clinical Assistant Professor of Psychiatry and Medicine, IU School of Medicine www.IndianaPolyclinic.com Version May 2020 1 Disclosures No disclosures currently (May 7, 2020) 2 Disclaimer ISDH Oral Health Program Disclaimer for courses or presentations: The information provided in this course or presentation does not, and is not intended to, constitute dental, medical, or legal advice; instead, all information, content, and materials available in this course or presentation are for general informational purposes only. You should contact an outside dentist, physician, or attorney to obtain dental, medical, or legal advice and prior to acting, or refraining from acting, on the basis of information contained in this course or presentation. All liability with respect to actions taken or not taken based on the contents of this course or presentation are hereby expressly disclaimed. 3 Goals of Pain Management • Decrease pain • Increase function • Utilize medications that limit unacceptable side effects, including addiction 4 Goals of This Presentation • Gain knowledge of appropriate use of NSAIDs and acetaminophen for pain management in dentistry • Improve insight into benefits and adverse effects of various NSAIDs • Learn appropriate alternatives to opioid use for pain management 5 Opioids: Use with Caution • Use of opioids for
    [Show full text]
  • The Challenge of Drug-Induced Aseptic Meningitis Revisited
    Letters cardioverter-defibrillator generator replacements and upgrade procedures: brospinal fluid (CSF) findings and reviews added to the litera- results from the REPLACE registry. Circulation. 2010;122(16):1553-1561. ture from 1999 to date. Tables have been assembled from 6. Kramer DB, Buxton AE, Zimetbaum PJ. Time for a change: a new approach to information derived from 192 studies (these data are avail- ICD replacement. N Engl J Med. 2012;366(4):291-293. able from the authors on request). The Challenge of Drug-Induced Aseptic Results | Four groups of drugs continue to be associated Meningitis Revisited with DIAM (Table 1): nonsteroidal anti-inflammatory Cases of drug-induced aseptic meningitis (DIAM) are likely drugs (NSAIDs), antibiotics, immunosuppressive- underreported, and only a few reviews of the literature have immunomodulatory (IS-IM), and antiepileptic drugs.1 Prior been performed. We have updated (to February 2014) a pre- exposure to the associated drug was present in 26% to 35% vious review (1999)1 to identify newer agents associated with of cases (Table 1). The interval between exposure and men- DIAM, as well as distinctive new features. ingitis ranged from minutes to 5 months (Table 1). Most patients presented with headache, fever, meningismus, and Methods | Using the MEDLINE database, we searched the lit- mental status changes (Table 2). Underlying systemic disor- erature to February 2014 and included those cases with cere- ders were often present, particularly systemic lupus ery- Table 1. Drugs Involved in Drug-Induced
    [Show full text]
  • Piroxicam 0.5%
    Patient Information Leaflet 2D PIROXICAM 0.5% GEL code Piroxicam Read all of this leaflet carefully before you start These potentially life-threatening skin rashes are often using this medicine because it contains important accompanied by flu-like symptoms. The rash may progress to information for you. widespread blistering or peeling of the skin. • Please keep this leaflet. You may need to read it again. The highest risk for occurrence of serious skin reactions is • If you have any further questions, ask your doctor within the first weeks of treatment. or pharmacist. If you have developed Stevens-Johnson syndrome or 2D 2D code • This medicine has been prescribed for you only. Do toxic epidermal necrolysis with the use of piroxicam, code not pass it on to others. It may harm them, even if you must not be re-started on piroxicam at any time. their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or Treatment should be discontinued at the first appearance of pharmacist. This includes any possible side effects not listed skin rash, blistering and peeling of the skin, mucosal lesions, in this leaflet. See section 4. or any other sign of hypersensitivity. If you develop a rash or skin symptoms, you should stop using piroxicam immediately, What is in this leaflet: seek prompt medical advice and tell your doctor that you are 1. What Piroxicam 0.5% Gel is and what it is used using this medicine. These reactions have not been associated for with topical piroxicam, but the possibility of occurring with 2.
    [Show full text]
  • FELDENE (Piroxicam) in Pregnant Women
    FELDENE® (piroxicam) CAPSULES 10 mg and 20 mg For Oral Use Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). • FELDENE is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). DESCRIPTION FELDENE® contains piroxicam which is a member of the oxicam group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each maroon and blue capsule contains 10 mg piroxicam, each maroon capsule contains 20 mg piroxicam for oral administration. The chemical name for piroxicam is 4-hydroxyl-2-methyl-N-2-pyridinyl-2H-1,2,-benzothiazine-3-carboxamide 1,1-dioxide. Piroxicam occurs as a white crystalline solid, sparingly soluble in water, dilute acid, and most organic solvents. It is slightly soluble in alcohol and in aqueous solutions. It exhibits a weakly acidic 4-hydroxy proton (pKa 5.1) and a weakly basic pyridyl nitrogen (pKa 1.8). The molecular weight of piroxicam is 331.35. Its molecular formula is C15H13N3O4S and it has the following structural formula: 4′ 3′ 5′ OH O 5 C NH 6′ 6 4 2′ 3 N 2 7 1 N S CH3 8 O 2 Reference ID: 3708816 The inactive ingredients in FELDENE capsules include: Blue 1, Red 3, lactose, magnesium stearate, sodium lauryl sulfate, starch.
    [Show full text]
  • Comparison Between Preoperative Use of Sublingual Piroxicam With
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 17, Issue 10 Ver. 9 (October. 2018), PP 80-84 www.iosrjournals.org Comparison Between Preoperative Use of Sublingual Piroxicam with that of Oral Ketorolac on Postoperative Pain Following Single Visit Root Canal Therapy –A Double Blind Randomized Control Study Akilan Balasubramanian1, Unnikrishna K2 1(Assistant professor, Department of conservative dentistry and endodontics, IRT medical college and hospital, The Tamilnadu Dr MGR medical university, India). 2(Senior resident, Department of conservative dentistry and endodontics, Government dental college, Kerala university of health sciences, India.) Corresponding Author: Akilan Balasubramanian Abstract: The purpose of this study was to determine if preoperative use of single dose of 20mg sublingual piroxicam and 20mg dispersible ketorolac would significantly reduce postendodontic pain, when compared with 600mg ibuprofen following single visit root canal treatment An additional objective was to compare the efficacy of sublingual piroxicam and dispersible ketorolac on post endodontic pain following single visit root canal treatment. A total of 70 adult patients consented to a double-blind, single-dose oral administration of 20mg of ketorolac, 20mg of piroxicam, 600 mg of ibuprofen, before single visit root canal therapy. Each Patient-reported visual analog scale ratings of pain intensity were conducted upon initial clinical presentation and at 6, 12, 24 and 48 hours and 72 h after completion of single visit root canal treatment. The results showed that at 6hrs period after single visit root canal treatment, all the three drugs Ketorolac, Piroxicam, Ibuprofen are equally effective in reducing post operative pain.
    [Show full text]
  • STUDIES with NON-STEROIDAL ANTI-INFLAMMATORY DRUGS By
    STUDIES WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS by Elizabeth Ann Galbraith M.Sc., C.Biol., M.I.Biol. A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Veterinary Medicine of the University of Glasgow Department of Veterinary Pharmacology M ay 1994 ProQuest Number: 11007888 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11007888 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 4kh! TUT GLASGOW UNIVERSITY ) LIBRARY i To Ian ii TABLE OF CONTENTS Acknowledgements v Declaration vi Summary vii List of tables xi List of figures xv Abbreviations xvii Chapter 1 - General Introduction 1 Chapter 2 - General Material and Methods 29 Chapter 3 - Studies with Flunixin 3.1 Introduction 43 3.2 Experimental Objectives 44 3.3 Materials and Methods 45 3.4 Experiments with Flunixin 48 3.5 Results of Oral Experiments with Flunixin 49 3.6 Results of Intravenous Experiments with Flunixin 53 3.7 Results of Subcutaneous Experiments with Flunixin 55 3.8 Discussion 57 3.9 Tables and Figures
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Annrheumd00427-0020.Pdf
    Annals of the Rheumatic Diseases, 1989; 48, 372-381 Evaluation of the effects of antiarthritic drugs on the secretion of proteoglycans by lapine chondrocytes using a novel assay procedure SIMON COLLIER AND PETER GHOSH From the Raymond Purves Research Laboratories (The University of Sydney) at the Royal North Shore Hospital of Sydney, St Leonards, NSW 2065, Australia SUMMARY A new method is described for separating free 35SO4- from 35SO4 labelled groteoglycans synthesised by rabbit articular chondrocytes cultured in the presence of excess 4 The procedure uses the low solubility product of barium sulphate to remove, by precipitation, free 35SO4- from culture medium. Optimum recovery of 35so4 labelled proteoglycans was achieved after papain digestion to release 35SO4-glycosaminoglycans, and addition of chondroitin sulphate before the precipitation step. Using this assay, we studied the effect of six drugs-indomethacin, diclofenac, sodium pentosan polysulphate, glycosaminoglycan polysulphate ester, tiaprofenic acid, and ketoprofen-on the secretion into the medium of labelled proteoglycans by lapine chondrocytes. The six drugs were tested at 0< 1, 1, 10, 50, and 100 I.g/ml over four consecutive 48 hour culture periods. A consistent concentration-response pattern was found for the four non-steroidal anti-inflammatory drugs (NSAIDs) studied. Generally they inhibited proteoglycan secretion at 50 and 100 [ig/ml but had no effect at lower concentrations. Inhibition of secretion was strongest with indomethacin and diclofenac at 50 and 100 ig/ml. In contrast with the NSAIDs studied, the two sulphated polysaccharides (sodium pentosan polysulphate and glycosaminoglycan polysulphate ester) at low concentrations increased proteoglycan secretion by chondrocytes, with maximal stimulation occurring at 1 [ig/ml.
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • Indocin® (Indomethacin) Oral Suspension
    INDOCIN® (INDOMETHACIN) ORAL SUSPENSION Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at a greater risk. (See WARNINGS.) • INDOCIN is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Suspension INDOCIN1 for oral use contains 25 mg of indomethacin per 5 mL, alcohol 1%, and sorbic acid 0.1% added as a preservative and the following inactive ingredients: antifoam AF emulsion, flavors, purified water, sodium hydroxide or hydrochloric acid to adjust pH, sorbitol solution, and tragacanth. Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. 1 Indomethacin is practically insoluble in water and sparingly soluble in alcohol. It has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali. The suspension has a pH of 4.0-5.0. The structural formula is: 1 Registered trademark of MERCK & CO., Inc., Whitehouse Station, NJ U.S.A. and licensed to Iroko Pharmaceuticals, LLC, Philadelphia, PA, U.S.A.
    [Show full text]
  • Toxic Effects of Non-Steroidal Anti- Inflammatory Agents in Rats
    African Journal of Biomedical Research, Vol. 9 (2006); 219 - 223 ISSN 1119 – 5096 © Ibadan Biomedical Communications Group Full Length Research Article Toxic Effects of Non-Steroidal Anti- Inflammatory Agents in Rats 1*Abatan, M. O, Lateef I. and 2Taiwo V.O. 1 Full-text available at Department of Veterinary Physiology & Pharmacology 2 http://www.ajbrui.com Department of Veterinary Pathology, & Faculty of Veterinary Medicine, University of Ibadan, Ibadan http://www.bioline.br/md Ibadan, Nigeria ABSTRACT The toxicosis of some non-steroidal anti-inflammatory drugs, piroxicam, indomethacin, phenylbutazone, and aspirin, which occasionally are locally used in Nigeria as rodenticides have been evaluated in rats using changes in the serum biochemical and haematological parameters as indices of toxicity. In the study, no clinical symptoms were observed in all the treatment groups except in the group of animals exposed to indomethacin which showed decreased feed intake, sluggishness, diarrhoea and some mortality were also recorded in the group. On the serum biochemical parameters, indomethacin and piroxicam caused increases in the level of total bilirubin and decreases blood urea nitrogen. Aspirin, indomethacin, and phenylbutazone produced increases in serum Received: aspartate aminotransferase and this increase is significant (P<0.05) with February, 2005 Accepted: the group treated with indomethacin compared to the control group. November, 2005 Indomethacin also caused significant (P<0.05) increase in the level of Published serum alanine aminotransferase. None of the treatment groups produced September, 2006 significant changes in haematological parameters except that indomethacin produced significant increase (P<0.05) in the total white blood cell count. Histological studies revealed that indomethacin also caused mild periportal hepatic necrosis and kupffer cell proliferation.
    [Show full text]